Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-11-20

Clinical Trial Update: Treatment of Septic Shock by Inhibiting Autodigestion and Preserving Gut Integrity With Enteric LB1148 [Phase 2]

View source ↗

Summary

Phase 2 trial update for LB1148 in septic shock; study terminated with posted results in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LB1148 (LB1148)

Snippet

Sponsor: Leading BioSciences, Inc | Conditions: Septic Shock | Phase 2 | Status: TERMINATED | Results posted: 2017-11-20